ZYME Graph | ZYMEWORKS INC.

ZYME Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $4.59M; Research and development (m); Income tax -$273.00K; Net income -$45.02M.
2026-03-31: Revenue $2.41M; Research and development (m); Income tax -$2.19M; Net income -$44.16M.
2025-12-31: Revenue $2.52M*; Research and development (m); Income tax -$270.00K*; Net income -$41.21M*.
2025-09-30: Revenue $27.61M; Research and development (m); Income tax $1.34M; Net income -$19.60M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Income tax	Net income
2026-06-30	$4.59M	(m)	-$273.00K	-$45.02M
2026-03-31	$2.41M	(m)	-$2.19M	-$44.16M
2025-12-31	$2.52M*	(m)	-$270.00K*	-$41.21M*
2025-09-30	$27.61M	(m)	$1.34M	-$19.60M
2025-06-30	$48.73M	(m)	-$186.00K	$2.32M
2025-03-31	$27.11M	(m)	$496.00K	-$22.64M
2024-09-30	$16.00M	(m)	$226.00K	-$29.85M
2024-06-30	$19.24M	(m)	$68.00K	-$37.69M
2024-03-31	$10.03M	$32.04M	$75.00K	-$31.65M
2023-12-31	(m)	$25.52M*	(m)	(m)
2023-09-30	$16.51M	$32.77M	$1.11M	-$28.69M
2023-06-30	$7.00M	$39.41M	$1.65M	-$51.15M
2023-03-31	$35.58M	$45.91M	$1.39M	-$24.35M
2022-09-30	$2.63M	$37.10M	-$29.00K	-$47.85M
2022-06-30	$5.44M	$56.02M	-$9.00K	-$64.62M
2022-03-31	$1.92M	$62.51M	-$74.00K	-$72.63M
2021-09-30	$4.39M	$49.89M	$764.00K	-$60.58M
2021-06-30	(m)	(m)	(m)	-$67.52M
2021-03-31	(m)	(m)	(m)	-$44.59M

Revenue and expense 6 month

Period end	Revenue	Research and development	Income tax	Net income
2026-06-30	$7.00M	(m)	-$2.46M	-$89.18M
2025-06-30	$75.84M	(m)	$310.00K	-$20.32M
2024-06-30	$29.27M	(m)	$143.00K	-$69.34M
2023-06-30	$42.58M	$85.32M	$3.04M	-$75.50M
2022-06-30	$7.36M	$118.53M	-$83.00K	-$137.24M

Revenue and expense 9 month

Period end	Revenue	Research and development	Income tax	Net income
2025-09-30	$103.45M	(m)	$1.65M	-$39.92M
2024-09-30	$45.27M	(m)	$369.00K	-$99.19M
2023-09-30	$59.09M	$118.09M	$4.15M	-$104.19M
2022-09-30	$9.99M	$155.63M	-$112.00K	-$185.09M
2021-09-30	$6.81M	$144.89M	$855.00K	-$172.69M

Revenue and expense 12 month

Period end	Revenue	Research and development	Income tax	Net income
2025-12-31	$105.97M	(m)	$1.38M	-$81.13M
2024-12-31	$76.30M	(m)	$6.08M	-$122.69M
2023-12-31	$76.01M	$143.62M	-$568.00K	-$118.67M
2022-12-31	$412.48M	$208.60M	$10.89M	$124.34M
2021-12-31	$26.68M	$199.75M	-$516.00K	-$211.84M
2020-12-31	$38.95M	$171.20M	$429.00K	-$180.55M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Sarepta Therapeutics, Inc. (SRPT)	United States	$1.941B	-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)	United States	$1.962B	-5.38
Biohaven Ltd. (BHVN)	United States	$1.990B	-3.83
COMPASS Pathways plc (CMPS)		$1.812B	-4.87
ANI PHARMACEUTICALS INC (ANIP)	United States	$1.810B	18.77
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
Septerna, Inc. (SEPN)	United States	$1.783B	-63.01
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
Xencor Inc (XNCR)	United States	$1.776B	-7.33